What Iressa treats: main uses and benefits

Iressa, known by its generic name gefitinib, is a targeted therapy medication used primarily for the treatment of specific types of lung cancer. Unlike traditional chemotherapy, which affects all rapidly dividing cells, this medication is designed to interfere with specific molecular pathways that allow cancer cells to grow and spread.

Primary Indication

Iressa is indicated for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC). It is specifically used in cases where the cancer cells possess certain mutations in the Epidermal Growth Factor Receptor (EGFR). These mutations, known as EGFR tyrosine kinase mutations, cause the receptor to be overactive, sending constant signals for the cell to divide and survive.

Mechanism of Action

As an EGFR tyrosine kinase inhibitor, Iressa works by binding to the intracellular portion of the receptor. By blocking this signaling pathway, the medication helps to:

• Slow down or stop the growth of the tumor.
• Induce cell death in cancer cells that are dependent on the EGFR pathway.
• Reduce the ability of the cancer to spread to other parts of the body.

Clinical Benefits

For patients whose tumors harbor the relevant genetic mutations, treatment with Iressa may offer several clinical advantages:

• Tumor Shrinkage: Many patients experience a reduction in the size of their primary tumor and metastatic lesions.
• Progression-Free Survival: The medication can extend the period during which the disease remains stable and does not worsen.
• Symptom Management: By controlling tumor growth, the treatment may help alleviate common symptoms associated with advanced lung cancer, such as coughing, shortness of breath, and chest pain.
• Targeted Approach: Because it targets specific mutations, it provides an alternative for patients who may not be suitable candidates for certain chemotherapy regimens or who have not responded to previous treatments.

Iressa (gefitinib) is a targeted therapy indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have specific activating mutations in the Epidermal Growth Factor Receptor (EGFR) gene (exon 19 deletions or exon 21 (L858R) substitution mutations). An FDA-approved test must confirm these mutations before treatment initiation.

---

Contraindications and Patient Safety

Iressa is not appropriate for everyone. Patients should not use Iressa if they have a known hypersensitivity or severe allergic reaction to gefitinib or any of its inactive ingredients. Due to the potential for fetal harm, pregnant women should not take Iressa, and women of reproductive potential must use effective contraception during treatment and for at least two weeks afterward. Breastfeeding is also contraindicated.

Cautious use, dose interruption, or permanent discontinuation may be necessary for patients who develop certain severe side effects, including confirmed Interstitial Lung Disease (ILD), severe hepatic impairment (liver failure), gastrointestinal perforation, or persistent ulcerative keratitis (a severe eye disorder). Regular monitoring and immediate consultation with a healthcare provider are essential for managing potential toxicities.

Iressa (gefitinib) is metabolized primarily by the CYP3A4 enzyme in the liver, meaning its levels in the body can be significantly affected by other medicines.

Interacting Product Category	Effect on Iressa Levels	Regulatory Guidance
Strong CYP3A4 Inducers (e.g., rifampicin, phenytoin, St John’s wort)	Decreases Iressa levels, potentially reducing its effectiveness.	Avoid concomitant use.
Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)	Increases Iressa levels, potentially increasing the risk of side effects.	Monitor closely for adverse reactions.

Products Affecting Gastric pH Iressa requires an acidic environment for proper absorption. Medicinal products that cause a significant, sustained increase in gastric pH, such as Proton Pump Inhibitors (PPIs) (e.g., omeprazole, lansoprazole) or H2-antagonists (e.g., ranitidine), may reduce the amount of Iressa absorbed, which may decrease its effectiveness. Concomitant use with PPIs should be avoided if possible. Antacids taken regularly close to the Iressa dose may have a similar effect, and administration should be spaced out (e.g., 6 hours apart) if necessary.

Anticoagulants Reports have documented increased International Normalized Ratio (INR) and/or bleeding events in some patients taking Iressa with warfarin. Patients using warfarin must have their prothrombin time (PT) or INR monitored regularly during concurrent treatment.

Targeted Inhibition of EGFR Tyrosine Kinase

Iressa (gefitinib) is a small-molecule inhibitor that acts directly upon the intracellular tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR). The mechanism involves competitive and reversible binding to the ATP-binding pocket, which immediately blocks the receptor’s ability to undergo autophosphorylation. This prevents the activation signal required for cellular proliferation and survival.

Disruption of Malignant Proliferation Signaling

This molecular blockade leads to the functional suppression of critical downstream pathways, specifically the Ras/MAPK and PI3K/AKT cascades. Interference with these survival signals forces the malignant cells into cell cycle arrest and subsequent apoptosis (programmed cell death), resulting in the physiological consequence of reduced proliferation and viability within the affected cell population.

Mechanistic Constraint Defined by Mutational Status

The inhibitory mechanism is intrinsically linked to the presence of specific activating EGFR mutations (e.g., L858R, Exon 19 deletions). The mechanism demonstrates significantly lower binding affinity and functional inhibitory capacity for wild-type EGFR compared to the mutated form. Secondary resistance mutations, such as the T790M substitution, can structurally impede the drug's binding, functionally constraining the mechanism's long-term inhibitory capacity.

Administration Method

Iressa is an oral medication provided in tablet form. It is intended to be swallowed whole with water and can be taken at the same time each day to maintain a consistent level of the medication in the body. The tablets may be taken with or without food.

Alternative Administration for Swallowing Difficulties

For individuals who have difficulty swallowing tablets whole, the medication can be dispersed in water. This involves placing the tablet in half a glass of plain, non-carbonated drinking water. No other liquids should be used. The tablet should be stirred into the water without being crushed until it has fully dispersed, which typically takes several minutes.

The resulting dispersion should be swallowed immediately. To ensure that the full amount of the medication is consumed, the glass should be rinsed with another half glass of water, which is then also swallowed.

Use via Gastric Tube

If necessary, the dispersion prepared in non-carbonated water can also be administered through a gastric tube. In such cases, the tube should be flushed with water following administration to ensure the entire dose has been delivered.

Research Evidence: Overview of Clinical Studies

This section provides a summary of the clinical research for Iressa (gefitinib), focusing on the types of studies conducted, the patient groups examined, and the outcomes measured, as reported in authoritative scientific literature and regulatory documents. Research provides context but not individual predictions. Findings describe group patterns, not personal outcomes.

---

Evidence for First-Line Use in EGFR-Mutated NSCLC

The largest body of research for Iressa research explored patient groups with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors have specific Epidermal Growth Factor Receptor (EGFR) activating mutations. Research in this context was primarily based on large, international Randomized Controlled Trials (RCTs). These studies were designed to compare Iressa as an initial, single-agent therapy against standard platinum-based chemotherapy.

The studies contained measured outcomes such as Progression-Free Survival (PFS), which is the time until the disease started to worsen or progress. The studies also monitored the Objective Response Rate (ORR), which tracks the percentage of patients who experienced a measurable reduction in tumor size during the study period. In this molecularly-selected group, studies reported measurements of PFS that were observed in the Iressa group compared to the chemotherapy group. Research also explored changes in disease-associated symptoms, such as cough or shortness of breath. Findings help contextualize how patients reported their experience.

---

Evidence from Initial Trials in Previously Treated NSCLC

Research explored patient groups with advanced NSCLC whose disease had progressed following standard chemotherapy regimens. This early research included Phase II studies that were conducted on broader populations, meaning patients were not initially selected based on their tumor's EGFR mutation status. Subsequent large-scale Phase III studies later compared Iressa against supportive care in this broad, unselected group. However, the large Phase III studies did not report a measurable difference in the Overall Survival endpoint for the broad, unselected patient group.

The evidence suggests that the measurable tumor activity observed in the early research contributed to the change in research focus toward the molecularly-defined subgroup where tumor activity was observed in some studies.

---

Scientific Gaps and Areas of Uncertainty

Final findings for Overall Survival (OS)—how long patients lived after starting treatment—data show patterns related to this outcome between the Iressa group and the chemotherapy group in many key trials. The research structure regarding the high rate of crossover, where patients switch treatments during the study, may affect the ability to isolate and interpret long-term survival measurements. Data are still emerging to fully characterize the long-term effects and the consistency of outcomes across all potential patient scenarios, meaning certainty remains low in certain areas.

Common questions about Iressa (FAQ)

Q: What is Iressa (gefitinib)?

A: Iressa (gefitinib) is a type of targeted therapy drug used to treat certain kinds of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. It belongs to a class of drugs called epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Gefitinib works by blocking the activity of the EGFR protein, which is often overactive in these cancer cells and helps them grow and divide. It is typically used for patients whose cancer cells have specific EGFR gene mutations.

---

Q: How is Iressa taken?

A: Iressa is taken by mouth as a tablet. The usual dose is one 250 mg tablet once daily. It can be taken with or without food. It is important to swallow the tablet whole with water and not to crush or chew it. If you miss a dose, you should take it as soon as you remember, unless it is less than 12 hours until your next dose. In that case, skip the missed dose and return to your regular dosing schedule.

---

Q: What are the most common side effects of Iressa?

A: The most common side effects often include:

• Diarrhea: This can range from mild to severe.
• Skin reactions: Such as a rash, acne-like breakouts, dry skin, and itching.
• Nausea and vomiting.
• Loss of appetite.
• Eye problems: Such as dry eyes or irritation.

Serious, but less common, side effects can include liver problems, and a serious lung condition called interstitial lung disease (ILD), which requires immediate medical attention if symptoms like new or worsening shortness of breath, cough, or fever occur.

---

Q: Can I take Iressa if I have liver problems?

A: Yes, but with caution. Iressa is processed by the liver. Patients with pre-existing, severe liver impairment may need to have their treatment managed carefully. Your healthcare provider will likely perform blood tests to check your liver function before and during treatment to monitor for any changes. They will decide if Iressa is safe for you based on the severity of your condition and test results.

---

Q: What should I avoid while taking Iressa?

A: You should avoid taking certain medications and foods that can interact with Iressa and affect how it works. These include:

• Certain acid-reducing medications (like proton pump inhibitors or H2-receptor antagonists), which can reduce Iressa absorption. Antacids may be used, but with a gap of several hours.
• Certain antibiotics, antifungals, and antiviral medicines.
• Herbal supplements, particularly St. John's wort.
• Grapefruit or grapefruit juice.

Always tell your healthcare provider about all the medications, over-the-counter drugs, and herbal supplements you are taking. They can provide specific guidance on what to avoid or manage.

Official Storage and Disposal Requirements for Iressa (Gefitinib) Tablets

Iressa must be stored according to specific regulatory guidelines to maintain its stability and effectiveness. The official requirements are:

Storage Component	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection	Keep protected from moisture and direct light.
Handling Constraints	Must be kept from freezing and away from excessive heat.
Child Safety	Keep out of the reach of children.

The medicine must remain in its closed container to uphold its integrity and is stable for up to 48 months when stored correctly. Unused or expired Iressa must not be flushed down a toilet or poured into a drain. Disposal should strictly follow the applicable local and national procedures for unused pharmaceuticals.